GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Sai Parenterals Ltd

Sai Parenterals Secures USD 11 Million Order for Anti TB Products

ORDERS ▲ Positive Development LOW RISK
📅 Filed on BSE: 28 May 2026, 08:13 PM IST  ·  BSE ID: ef219f05-8d9b-4717-a7c0-b763cd73ac47
View Original BSE Filing (PDF)
💡
In Simple Terms
Sai Parenterals won a 10-year contract to supply anti TB products worth USD 11 million to a Philippine company.
🤖 AI Summary
  • Sai Parenterals received a purchase order worth USD 11 million (Rs. 104.50 Crores).
  • The order is from PILL CORP, Bulacan, Philippines.
  • It involves the supply of anti TB products on an exclusivity basis.
  • The contract duration is for ten years, effective June 1, 2026.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Order Value (USD)
USD 11 million
Order Value (INR)
Rs. 104.50 Crores
Contract Term
Ten (10) years
Effective Date
01 June 2026
🏢 How This Affects the Company
📈
Business Impact
This order establishes a long-term supply agreement for anti TB products in the Philippines market, introducing an exclusivity clause for a decade.
💰
Financial Impact
The order represents a significant revenue stream of USD 11 million over ten years, subject to periodic purchase order releases.
⚙️
Operational Impact
Execution of this order will require ongoing supply chain management and production planning to meet the ten-year commitment.
⚠️
Risk Impact
The exclusivity and long-term nature of the contract mitigate some market entry risks but introduce dependence on a single international client.
👥 What This Means For Shareholders
✅
Action Required
No specific action is required from shareholders based on this order win announcement.
👤
Who Is Affected
All shareholders are affected by the potential for increased revenue and market diversification arising from this international contract.
🔍
Management Signal
This order win signals management's focus on expanding international reach and securing long-term supply agreements.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Periodic purchase order releases against the contract.
Company's financial results for periods including FY27 onwards.
Any updates on contract extension or revision from PILL CORP.
LOW RISK The filing details a confirmed order with clear terms and no immediate identified risks in the disclosure.
💡 Investor Takeaway
Sai Parenterals secured a USD 11 million order for anti TB products from PILL CORP, Philippines, with a ten-year exclusivity contract starting June 1, 2026.
⚖️ Strengths & Concerns

✅ Positives

  • Secured a USD 11 million international order for anti TB products.
  • Contract includes a ten-year exclusivity term for the Philippines market.
❓ Frequently Asked Questions
What is the value of the purchase order received by Sai Parenterals?
Sai Parenterals received a purchase order worth USD 11 million, equivalent to Rs. 104.50 Crores.
Who awarded the purchase order to Sai Parenterals?
The purchase order was awarded by PILL CORP, located in Bulacan, Philippines.
What is the nature of the order awarded to Sai Parenterals?
The order is for the supply of anti TB products on an exclusivity basis for the Philippines market.
What is the duration of the contract awarded to Sai Parenterals?
The contract has a term of ten (10) years, commencing from the effective date of 01 June 2026.
Does Sai Parenterals have any interest in PILL CORP?
No, the promoter, promoter group, or group companies of Sai Parenterals do not have any interest in PILL CORP.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.